Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Obesity

In brief

To assess the safety and tolerability of AMG 171 as single or multiple doses in subjects with obesity

Key facts

Study ID

NCT04199351

Run by

Amgen

People needed

60

Starts

2019-12-13

Expected to finish

2021-09-10

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females with ages between 18 and 65 years old, inclusive
• Except for obesity, otherwise healthy
• Body mass index (BMI) greater than or equal to 30.0 kg/m2 and less than or equal to 40.0 kg/m2 at screening
• Other Inclusion criteria may apply

You may not qualify if…

• Currently receiving treatment in another investigational device or drug study
• Women of childbearing potential
• History or evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
• Other Exclusion criteria may apply

Where it is running

• Anaheim Clinical Trials — Anaheim, California, United States
• Orange County Research Center — Tustin, California, United States
• Clinical Pharmacology of Miami, LLC — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.